Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX™ in Patients with Ménière's Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Otonomy (OTIC) PT Lowered to $9 at Cowen Amid Otividex Failure; Dramatic And Fast Changes Needed
August 30, 2017 10:44 AM EDTCowen analyst Ken Cacciatore lowered his price target on Otonomy (NASDAQ: OTIC) to $9.00 (from $55.00) while maintaining an Outperform rating following the Otividex failure.
Cacciatore said said the company will now need to make dramatic and rapid spending reductions and the focus... More
UPDATE: Otonomy (OTIC) Plunges Over 77% After Phase 3 Trial of OTIVIDEX Fails
August 30, 2017 7:33 AM EDT(Updated - August 30, 2017 7:37 AM EDT)
Otonomy (NASDAQ: OTIC) dropped 77% after shares resumed following a brief trading halt pending results for its AVERTS-1 Phase 3 clinical trial of OTIVIDEX in patients with Ménières disease. The clinical trial missed its primary endpoint.
... MoreOtonomy (OTIC) to Resume Trading at 7:30 AM ET
August 30, 2017 7:25 AM EDTOtonomy (NASDAQ: OTIC) to Resume Trading at 7:30 AM ET
... More